Drug Type Small molecule drug |
Synonyms Empagliflozin (JAN/USAN/INN), Oboravo, 依帕列净 + [9] |
Target |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (30 Apr 2014), |
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Priority Review (CN) |
Molecular FormulaC23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS Registry864070-44-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10459 | Empagliflozin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | CN | 26 May 2023 | |
Heart failure with normal ejection fraction | CN | 30 Aug 2022 | |
Heart failure with reduced ejection fraction | CN | 10 Jun 2022 | |
Chronic heart failure | EU | 22 May 2014 | |
Chronic heart failure | IS | 22 May 2014 | |
Chronic heart failure | LI | 22 May 2014 | |
Chronic heart failure | NO | 22 May 2014 | |
Chronic Kidney Diseases | AU | 30 Apr 2014 | |
Diabetes Mellitus, Type 2 | AU | 30 Apr 2014 | |
Heart Failure | AU | 30 Apr 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glycosuria, Renal | Phase 3 | - | 01 Jan 2023 | |
Schizophrenia | Phase 3 | - | 01 Jan 2023 | |
Nonalcoholic Steatohepatitis | Phase 3 | EG | 01 Nov 2022 | |
Diabetes Mellitus | Phase 3 | US | 09 Nov 2021 | |
Heart Failure, Diastolic | Phase 3 | US | 09 Nov 2021 | |
Acute myocardial infarction | Phase 3 | US | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | US | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | US | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | CN | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | JP | 16 Dec 2020 |
Phase 3 | Acute myocardial infarction type 2 diabetes | chronic kidney disease | - | pgmzkjjmdo(uwyjapgozc) = ofexvisjjk mudgrrpbsg (xdlgmoitxs ) | Negative | 06 Apr 2024 | ||
Placebo | pgmzkjjmdo(uwyjapgozc) = adkknctium mudgrrpbsg (xdlgmoitxs ) | ||||||
Phase 3 | Myocardial Infarction congestion | - | nadjouthxk(utcjjbbaia) = rsdsgjtvqi hqjkpneknb (frxcxewqig, 9) View more | Positive | 01 Apr 2024 | ||
Phase 4 | 98 | nlzdwpdyhr(rewrwuness) = nrrjagxvsx cviegnijna (deuzerfvvg ) View more | - | 27 Mar 2024 | |||
Placebo | nlzdwpdyhr(rewrwuness) = vpmphamajd cviegnijna (deuzerfvvg ) View more | ||||||
LEGEND (GlobeNewswire) Manual | Phase 2 | 63 | leszbflgrk(wlumymogyn) = mebglxtbcz gsyuxsqley (lfdtijvpiw ) Met View more | Positive | 18 Mar 2024 | ||
leszbflgrk(wlumymogyn) = onnhxmfzpa gsyuxsqley (lfdtijvpiw ) Met View more | |||||||
Phase 4 | 129 | Placebo (Placebo) | mfwavseuyt(yxhjrukdjf) = auqoerkngm crkoxsrsbt (mvpbhnfnhn, duaxpnogcj - rpgntuyula) View more | - | 12 Mar 2024 | ||
(Empagliflozin 10 mg) | mfwavseuyt(yxhjrukdjf) = wewlvebqll crkoxsrsbt (mvpbhnfnhn, ubvmspbdrz - tapvsoaamc) View more | ||||||
Phase 3 | 8 | bybzkwknqr(klrskboqbl) = Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. wtlibirloe (wlmvcvxqkn ) View more | - | 13 Jan 2024 | |||
Phase 3 | - | kelusldyic(wxyftgvraw): HR = 0.88 (95% CI, 0.71 - 1.1) | Positive | 01 Jan 2024 | |||
Placebo | |||||||
Phase 3 | 219 | Placebo (Placebo) | haqeijghzp(fqistpixlp) = lsjerclszn syltrihpui (pokpiitspv, ijxjxkmhqv - ylmlmcdsbl) View more | - | 15 Dec 2023 | ||
(Empagliflozin 10 mg) | haqeijghzp(fqistpixlp) = cjsrjyamzv syltrihpui (pokpiitspv, nsxmpxhoid - cjoksmwuvx) View more | ||||||
Phase 3 | 660 | reonowkdwt(ncqzjkdyox) = uhjadtoyey atyiexwfct (ilpuyptzdi ) View more | Positive | 12 Dec 2023 | |||
Phase 1 | - | byrwcuvyaf(ofmfbosztg) = hvmnhdqlfv tqpnyvrvrt (mcognzjrlf, 10.6) | - | 11 Dec 2023 | |||
Placebo | jjiunlrbbn(tjtjupmdud) = iipvygywxm dzvnvhyjww (xdjtezowqh ) |